<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Intravitreal Aflibercept 8 mg - CANDELA</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
  <link rel="stylesheet" href="assets/css/styles.css">
  <link rel="stylesheet" href="assets/fonts/fontawesome-all.min.css">
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.7.0/jquery.min.js"></script>
  <script src="assets/js/javascript.js"></script>
</head>



<body>
  <div class="row">
    <h3 style="font-size: 28px; width: 100%; color: white; font-weight: bold; background: #00617f; padding-top: 10px; padding-bottom: 10px;padding-left: 25px;">Intravitreal Aflibercept 8 mg - CANDELA</h3>
  </div>

    
  <div>
    <button type="button" class="btn btn-back" id="back_button" onclick="location.href='index.html';">IVT-AFL 8 mg Overview</button><br>

    <h4>
      CANDELA
    </h4>
    <div class="card">
      <ul class="nav nav-tabs" role="tablist">
        <li class="nav-item" role="presentation"><a class="nav-link active" id="summary_tab" data-bs-toggle="tab" data-bs-target="#summary" href="#summary" role="tab">Summary</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id= "design_tab" data-bs-toggle="tab" data-bs-target="#design" href="#design" role="tab">Design</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id= "results_tab" role="tab" data-bs-toggle="tab" href="#results">Results</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id= "safety_tab" role="tab" data-bs-toggle="tab" href="#safety">Safety</a>
        </li>
        <li class="nav-item" role="presentation"><a class="nav-link" id = "reference_tab" role="tab" data-bs-toggle="tab" href="#reference">Reference</a>
        </li>
      </ul>
    </div>
  
  
      
    
  
    <div class="tab-content">
      <div id="summary" class="tab-pane show active" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Summary<sup>1</sup>
          </h1>
          <ul class="bullet">
            <li>
              The <a href="https://www.clinicaltrials.gov/study/NCT04126317" target="_blank">CANDELA</a> study was a randomized, multicenter, single-masked, Phase 2 study that evaluated the efficacy and safety profile of IVT-AFL 8 mg vs 2 mg in treatment naïve patients with nAMD.
            </li>
            <li>
              More patients treated with 8 mg vs 2 mg IVT-AFL had no fluid in the center subfield at Week 16 (51% vs 34%, respectively; p=0.0770; primary endpoint) and no fluid in the macula at Week 44 (32% vs 15%, respectively; p=0.0395).
            </li>
            <li>
              The average letter improvement from baseline was greater with IVT-AFL 8 mg vs 2 mg (7.9 vs 5.1 EDTRS letters, respectively).
            </li>
            <li>
              The CANDELA study was not powered to determine statistical significance. Overall, no new safety signals were identified; the overall safety of 8 mg IVT-AFL appears to be similar to that of 2 mg IVT-AFL.
            </li>
          </ul>
        </div><br><br>
      </div>
  
      <div id="design" class="tab-pane"  role="tabpanel">
        <div class="container-fluid">
          <h1>
            Design<sup>1</sup>
          </h1>
          <ul class="bullet">        
            <li>
              Patients with active subfoveal CNV secondary to nAMD and BCVA ETDRS score of 78 to 24 letters were randomized 1:1 to receive IVT-AFL 8 mg (n=53) or IVT-AFL 2 mg (n=53) q4 for 3 months (baseline, Week 4, and Week 8), followed by q12 dosed (Week 20 and Week 32). 
            </li>
            <li>
              Patients were permitted to receive PRN treatment at Weeks 24, 28, 36, and 40 if they met the following criteria: loss of ≥5 letters from Week 20 due to disease progression or anatomical findings considered life threatening (e.g., worsening/persistent retinal fluid, new/worsening retinal PED, new/persistent hemorrhage) and were followed for 44 weeks. 
            </li>
            <li>
              The primary endpoint was proportion of patients without retinal fluid in the center subfield at Week 16.
            </li>
          </ul>
          <div class="container-collapse">
            <a class="btn btn-collapse" data-bs-toggle="collapse" aria-expanded="false" aria-controls="collapse-1" href="#collapse-1" role="button">Click to Expand/Collapse <br> Dosing Regimens
            </a>
          </div>
  
            <div id="collapse-1" class="collapse">
              <h2>
                Dosing and Visit Schedule
              </h2>
              <div class="figure zoom">
                <img src="assets/img/dosing-CANDELA.PNG" 
                class="img-fluid">
            </div>
          </div>
        </div><br><br>
      </div> 
            
      <div id="results" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Results<sup>1</sup>
          </h1>
          <div class="accordion">
            <div class="accordion-item">
              <h2 class="accordion-header" id="heading 1">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-2">
                 Patients
                </button>
              </h2>
              <div id="collapse-2" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <ul class="bullet-collapse">
                    <li>
                      Of the 106 patients enrolled, 100 patients completed Week 44 of the study (8 mg, n=51; 2 mg, n=49). 
                    </li>
                    <li>
                      Baseline mean BCVA was 58.0±11.9 ETDRS letters. 
                    </li>
                    <li>
                      The mean number of injections was 5.8 for each group for the full analysis set. 
                    </li>
                    <li>
                      The total number of PRN injections administered was 33 in the 8 mg group and 38 in the 2 mg group, and fewer patients did not require PRN or additional treatment with 8 mg compared with 2 mg (53% vs 45%, respectively).
                    </li>
                  </ul>
                  </div>
                </div>
              </div>
                
            <div class="accordion-item">
              <h2 class="accordion-header" id="patients">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-4">
                  Primary Efficacy Endpoint
                </button>
              </h2>
              <div id="collapse-4" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <ul class="bullet-collapse">
                    <li>
                     More patients treated with 8 mg IVT-AFL had no fluid in the center subfield (defined as no IRF and no SRF on SD-OCT) compared with 2 mg at Week 16 (p=0.0770).
                    </li>
                    <li>
                      Furthermore, more patients had no fluid in the macula with 8 mg vs 2 mg at Week 44 (p=0.0395).
                    </li>
                    <li>
                      The CANDELA study was not powered to determine statistical significance.
                    </li>
                  </ul>
                  <h2>
                    Eyes Without Fluid in the Center Subfield and Macula at Weeks 16 and 44                  </h2>
                  <div class="figure-white">
                    <img src="assets/img/primary_outcome-CANDELA.PNG" 
                        class="img-fluid">
                  </div>
                </div>
              </div>
            </div>
  
            <div class="accordion-item">
              <h2 class="accordion-header" id="results">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-5">
                  Key Secondary Endpoints
                </button>
              </h2>
              <div id="collapse-5" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <ul class="bullet-collapse">
                    <li>
                      Changes in CRT and BCVA from baseline through Week 44 are summarized in the table below. 
                    </li>
                    <li>
                      The average letter improvement from baseline was greater with IVT-AFL 8 mg vs 2 mg (7.9 vs 5.1 EDTRS letters, respectively). 
                    </li>
                  </ul>
                  <h2>
                    Change in CRT and BCVA from Baseline to Week 44
                  </h2>
                  <div class="figure-white">
                    <img src="assets/img/secondary_outcomes-CANDELA.PNG" 
                      class="img-fluid">
                  </div>
                  <ul class="bullet-collapse">
                    <li>
                      The proportion of patients with vision loss of &ge;5, &ge;10, or &ge;15 letters with 8 mg vs 2 mg, respectively, was 11% vs 22%, 6% vs 10%, and 4% vs 6%.                    
                    </li>
                    <li>
                      The proportion of patients with vision gain of &ge;5, &ge;10, or &ge;15 letters with 8 mg vs 2 mg, respectively, was 57% vs 59%, 47% vs 35%, and 28% vs 18%.
                    </li>
                  </ul>
                </div>
              </div>
            </div>
          </div><br>
        </div>
      </div>
        

      <div id="safety" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Safety<sup>1</sup>
          </h1>
          <p style="margin-left: 35px; margin-top: -10px; font-size: 20px;">
            Overall, no new safety signals were identified; the overall safety of 8 mg IVT-AFL appears to be similar to that of IVT-AFL 2 mg.
          </p>
          <div class="container">
            <div class="row" style="margin-left: 30px; margin-right: 30px;">
              <div class="col" style="background-color: #e5eff2; margin-bottom: 10px;">
                <p style="margin-left: 10px; margin-bottom: 5px;font-size: 22px; text-decoration: underline">
                  Ocular Safety
                </p>
                <ul style="font-size: 20px;">
                  <li>
                    No vascular occlusive events
                    <ul>
                      There was 1 case of iritis in the 8 mg group, which was mild and resolved with topical therapy
                    </ul>
                  </li>
                  <li>
                    No IOP increases of clinical concern in either group
                  </li>
                </ul>
              </div>
              <div class="col" style="background-color: #e5eff2; margin-bottom: 10px;">
                <p style="margin-left: 15px; margin-bottom: 5px; font-size: 22px; text-decoration: underline">
                  Non-Ocular Safety
                </p>
                <ul style="font-size: 20px;">
                  <li>
                    2 cases (one in each treatment group) of non-serious worsening hypertension
                  </li>
                  <li>
                    No APTC AEs
                  </li>
                  <li>
                    One death in the 8 mg group (glioblastoma)
                  </li>
                </ul>
              </div>
            </div>
          </div>
          <br>
          <div class="container-collapse">
            <a class="btn btn-collapse" data-bs-toggle="collapse" aria-expanded="false" href="#collapse-6" role="button">Click to Expand/Collapse <br> Ocular TEAEs
            </a>
          </div>
  
            <div id="collapse-6" class="collapse">
              <h2>
                Ocular TEAEs in Study Eye through Week 44
              </h2>
              <div class="figure zoom">
                <img src="assets/img/safety-CANDELA.PNG" 
                class="img-fluid">
            </div>
          </div>
        </div>
      </div>
  
      <div id="reference" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Reference
          </h1>
          <ol style="margin-left: 30px; margin-right: 30px; margin-top: -20px; padding-right: 30px; padding-left: 30px; padding-bottom: 10px; padding-top: 10px; font-size: 20px;background-color: #f7f7f7;">
            <li>
              Brown, DM. CANDELA: High dose aflibercept for neovascular AMD, in Angiogenesis, Exudation, and Degeneration 2022. 2022. Bascom Palmer Eye Institute: Virtual.
            </li>
          </ol>
        </div>
      </div><br><br>
    </div>
  
    <footer class="fixed-bottom">
      <div class="container-fluid">
        <button type="button" class="btn btn-abbrev" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" onclick="changeIcon(this)" title="Abbreviations" data-bs-content="
          <strong>AE</strong> adverse event<br>
          <strong>APTC</strong> Anti-Platelet Trialists’ Collaboration<br>
          <strong>BCVA</strong> best-corrected visual acuity<br>
          <strong>CVN</strong> choroidal neovascularization<br>
          <strong>CRT</strong> central retinal thickness<br>
          <strong>ETDRS</strong> Early Treatment Diabetic Retinopathy Scale<br>
          <strong>IOP</strong> intraocular pressure<br>
          <strong>IRF</strong> intraretinal fluid<br>
          <strong>IVT-AFL</strong> intravitreal aflibercept<br>
          <strong>n</strong> number<br>
          <strong>nAMD</strong> neovascular age-related macular degeneration<br>
          <strong>PED</strong> pigment epithelial detachment<br>
          <strong>PRN</strong> pro re nata (as needed)<br>
          <strong>q4</strong> every 4 weeks<br>
          <strong>q12</strong> every 12 weeks<br>
          <strong>SRF</strong> subretinal fluid<br>
          <strong>TEAE</strong> treatment-emergent adverse event<br>">
        <i id ="fa" class="fas fa-list"></i>
        </button>
  
    <button type="button" class="btn btn-ref" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" title="Reference" onclick="changeIcon(this)" data-bs-content="
      <ol>
        <li>
          Brown, DM. CANDELA: High dose aflibercept for neovascular AMD, in Angiogenesis, Exudation, and Degeneration 2022. 2022. Bascom Palmer Eye Institute: Virtual.
        </li>
     </ol>">
     <i id="fa" class="fas fa-scroll"></i>
    </button>
      </div>
      <a href="#" id="scroll" style="display: none;"><span></span></a>
    </footer>   
  </div>
</div>

<script>  
  var popoverTriggerList = [].slice.call(document.querySelectorAll('[data-bs-toggle="popover"]'))
  var popoverList = popoverTriggerList.map(function (popoverTriggerEl) 
  {
    return new bootstrap.Popover(popoverTriggerEl)
  });
</script>
</body>

</html>